KAZIA THERAPEUTICS LTD
Business
Kazia Therapeutics is an emerging oncology-focused biotechnology company developing a portfolio of clinical-stage drug candidates. The company's lead program is Paxalisib, an orally administered PI3K/Akt/mTOR pathway inhibitor designed to treat brain cancers including glioblastoma, pediatric diffuse midline gliomas, and brain metastases, currently in multiple Phase I/II/III clinical trials sponsored by major research institutions. Kazia also develops EVT801, a VEGFR3 inhibitor licensed from Evotec for advanced solid tumors, which completed Phase I testing. The company operates through clinical development programs conducted primarily by external research organizations and funded largely by non-company sources.
Summary from 20-F filed 2025-11-07
Financials
Latest annual snapshot (FY2025, period end 2025-06-30). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-20.70M |
| Total assets | $6.06M |
| Total liabilities | $14.36M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is KAZIA THERAPEUTICS LTD's CIK number?
KAZIA THERAPEUTICS LTD's SEC CIK number is 0001075880 (1075880). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find KAZIA THERAPEUTICS LTD's SEC filings?
All of KAZIA THERAPEUTICS LTD's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.